Protas today announces a new partnership with UK-based portfolio biopharmaceutical company Apollo Therapeutics to advance its portfolio of therapeutic programmes.
Protas will provide expertise in designing streamlined clinical trials for a range of Apollo’s broad and diversified drug development programmes, in order to produce high-quality, robust and definitive clinical outcomes.
Apollo’s portfolio includes potential new treatments for some of the most common disease areas and has rich potential to result in meaningful treatment options for patients. This makes Apollo an ideal partner in Protas’ mission of reducing the burden of common diseases worldwide.
Prof Sir Martin Landray, CEO of Protas, said: “We are thrilled to be supporting Apollo with their ambitious and promising portfolio of therapies.
“Protas was set up to transform the way that trials are designed and delivered globally, to encourage the development of more effective treatments for common diseases.
“Collaborations with innovative companies like Apollo are vital in making this change possible, and we are looking forward to working with the team on this shared vision.”
Dr Richard Mason, CEO of Apollo Therapeutics, said: “This partnership with Protas will be hugely beneficial to our therapeutic aims and ability to develop those portfolio programmes focusing on large chronic disorders.
“With Protas’ experience, expertise and integrated approach, we aim to progress our portfolio, with the ultimate goal of providing innovative healthcare to as many patients as possible.”